BRPI0909198A2 - composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar - Google Patents

composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar

Info

Publication number
BRPI0909198A2
BRPI0909198A2 BRPI0909198A BRPI0909198A BRPI0909198A2 BR PI0909198 A2 BRPI0909198 A2 BR PI0909198A2 BR PI0909198 A BRPI0909198 A BR PI0909198A BR PI0909198 A BRPI0909198 A BR PI0909198A BR PI0909198 A2 BRPI0909198 A2 BR PI0909198A2
Authority
BR
Brazil
Prior art keywords
compound
antifolate
treating
preparing
pharmaceutical composition
Prior art date
Application number
BRPI0909198A
Other languages
English (en)
Inventor
Harish Pimplaskar K
Horvath Karol
Lebedev Mikhail
Original Assignee
Chelsea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chelsea Therapeutics Inc filed Critical Chelsea Therapeutics Inc
Publication of BRPI0909198A2 publication Critical patent/BRPI0909198A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BRPI0909198A 2008-04-07 2009-04-07 composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar BRPI0909198A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4299808P 2008-04-07 2008-04-07
US4299408P 2008-04-07 2008-04-07
PCT/US2009/039792 WO2009126639A1 (en) 2008-04-07 2009-04-07 Crystalline salt forms of antifolate compounds and methods of manufacturing thereof

Publications (1)

Publication Number Publication Date
BRPI0909198A2 true BRPI0909198A2 (pt) 2019-09-24

Family

ID=40749240

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909198A BRPI0909198A2 (pt) 2008-04-07 2009-04-07 composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar

Country Status (10)

Country Link
US (2) US20090253719A1 (pt)
EP (2) EP2282740A1 (pt)
JP (2) JP2011516560A (pt)
KR (1) KR20100132061A (pt)
CN (1) CN101981014A (pt)
AU (1) AU2009233829A1 (pt)
BR (1) BRPI0909198A2 (pt)
CA (2) CA2718544A1 (pt)
MX (2) MX2010010998A (pt)
WO (2) WO2009126637A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100132061A (ko) * 2008-04-07 2010-12-16 첼시 쎄라퓨틱스, 인코포레이티드 항엽산제 화합물의 결정 염 형태 및 이의 제조 방법
MX2012000437A (es) * 2009-07-08 2012-02-21 Chelsea Therapeutics Inc Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico.
AU2010315152A1 (en) * 2009-11-06 2012-06-14 Chelsea Therapeutics, Inc. Enzyme inhibiting compounds
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions
WO2012056285A1 (en) * 2010-10-25 2012-05-03 Fresenius Kabi Oncology Ltd. An improved process for the preparation of pemetrexed
WO2012078708A1 (en) * 2010-12-07 2012-06-14 Chelsea Therapeutics, Inc. Combination comprising methotrexate and an antifolate compound
FR2969167B1 (fr) 2010-12-15 2013-01-11 Arkema France Composition thermoplastique modifiee choc amelioree
FR2969161B1 (fr) 2010-12-15 2014-06-06 Arkema France Nouvelle poudre de polymere multi-etape coeur-ecorce, son procede de fabrication et composition comprenant celle-ci
FR2969158B1 (fr) 2010-12-15 2013-01-18 Arkema France Procede pour modifiants chocs et composition thermoplastique modifiee choc ayant une resistance hydrolytique amelioree
US20130018062A1 (en) * 2011-07-12 2013-01-17 Nair Madhavan G Pain therapy with metabolism blocked antifolates
TW201700458A (zh) * 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
BR112019002007B1 (pt) 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
EP4175672A1 (en) 2020-07-06 2023-05-10 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
EP4457229A1 (en) 2021-12-30 2024-11-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818753A (en) * 1987-09-18 1989-04-04 Sri International Synthesis and method of use for 2, 4 diaminoquinazoline
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
US4996206A (en) * 1989-12-11 1991-02-26 The Trustees Of Princeton University N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
US5073554A (en) * 1990-01-18 1991-12-17 Nair Madhavan G Two non-polyglutamatable antifolates
US5508281A (en) * 1991-04-08 1996-04-16 Duquesne University Of The Holy Ghost Derivatives of pyrido [2,3-d] and [3,2-d] pyrimidine and methods of using these derivatives
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
US5550128A (en) * 1994-09-09 1996-08-27 Nair; Madhavan G. Enantiomers of gamma methylene 10-deaza aminopterin and process for preparing the same
US5593999A (en) * 1995-06-07 1997-01-14 Nair; Madhavan G. Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
US20030162721A1 (en) * 1997-07-07 2003-08-28 Francesco Mehlem Pharmaceutical composition containing peptichemio
US5912251A (en) * 1998-01-17 1999-06-15 Nair; Madhavan G. Metabolically inert anti-inflammatory and anti-tumor antifolates
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CA2726789A1 (en) * 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
WO2002059114A1 (en) * 2000-11-28 2002-08-01 Genentech, Inc. Lfa-1 antagonist compounds
KR100685917B1 (ko) * 2000-12-27 2007-02-22 엘지.필립스 엘시디 주식회사 전계발광소자 및 그 제조방법
US20030181635A1 (en) * 2002-03-22 2003-09-25 Harry Kochat Process for coupling amino acids to an antifolate scaffold
US20040092739A1 (en) * 2002-11-13 2004-05-13 Zejun Xiao Process for synthesizing antifolates
US7060825B2 (en) * 2003-07-25 2006-06-13 Bionumerik Pharmaceuticals, Inc. Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
JP2008512490A (ja) * 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド 異常細胞増殖および炎症の障害を治療するための代謝的に不活性な葉酸拮抗剤
WO2006074416A1 (en) * 2005-01-07 2006-07-13 Health Research Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
KR20100132061A (ko) * 2008-04-07 2010-12-16 첼시 쎄라퓨틱스, 인코포레이티드 항엽산제 화합물의 결정 염 형태 및 이의 제조 방법

Also Published As

Publication number Publication date
WO2009126637A1 (en) 2009-10-15
JP2011516561A (ja) 2011-05-26
MX2010010998A (es) 2011-01-25
AU2009233829A1 (en) 2009-10-15
EP2282740A1 (en) 2011-02-16
EP2300441A1 (en) 2011-03-30
MX2010010999A (es) 2011-02-22
WO2009126639A1 (en) 2009-10-15
CN101981014A (zh) 2011-02-23
US20090253719A1 (en) 2009-10-08
CA2718330A1 (en) 2009-10-15
KR20100132061A (ko) 2010-12-16
CA2718544A1 (en) 2009-10-15
US20090253720A1 (en) 2009-10-08
JP2011516560A (ja) 2011-05-26

Similar Documents

Publication Publication Date Title
BRPI0909198A2 (pt) composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar
BRPI0909691A2 (pt) Composto, método para preparar um composto, e, composição farmacêutica
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI0807756A2 (pt) Método para produzir um l-aminoácido.
BRPI1010950A2 (pt) método para preparação de emulsão carregada de fármaco.
BRPI0922566A2 (pt) polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0908092A2 (pt) Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante
BRPI0917196A2 (pt) método para a preparação de um complexo, e, forma cristalina de um composto.
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BRPI0911898A2 (pt) processo para preparar compostos, e, composto.
BRPI1015983A2 (pt) composto, uso do composto, método para tratar um paciente, e, composição farmacêutica.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BR112012001998A2 (pt) solução oftálmica, uso de um composto, e, método para preparação de uma solução oftálmica.
BRPI0918736A2 (pt) método para produzir leite modificado.
BRPI0918955A2 (pt) preparação sólida, e, método para estabilizar um composto, e para melhorar a dissoulução de um composto
BRPI0917345A2 (pt) composição, e, método para produzir uma composição estabilizada.
BRPI1012047A2 (pt) compostos dímeros contendo oxazolidinona, composições e métodos para fazer e uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.